The Regents of the University of Minnesota

1. LivaNova USA, Inc. $677,824 252 payments
2. Regeneron Pharmaceuticals, Inc. $264,919 74 payments
3. Amicus Therapeutics, Inc. $224,828 174 payments
4. Celgene Corporation $206,689 6 payments
5. AstraZeneca Pharmaceuticals LP $91,985 3 payments
6. Bayer HealthCare Pharmaceuticals Inc. $84,331 8 payments
7. Swedish Orphan Biovitrum AB $73,667 6 payments
8. Ascendis Pharma, Inc. $70,411 16 payments
9. Mirati Therapeutics, Inc. $61,802 12 payments
10. Biogen, Inc. $49,790 1 payment

1. A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) $242,735 31 payments
2. Recover $166,564 171 payments
3. A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression $157,960 39 payments
4. A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Doses and Dose Regimens of Evinacumab in Patients With Persistent Hypercholesterolemia Despite Maximally Tolerated Lipid Modifying Therapy $147,994 44 payments
5. The RECOVERsUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes $98,140 7 payments
6. A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM) (JCAR017-BCM-003) $79,730 1 payment
7. Ni-0501-14 $73,667 6 payments
8. PhIII Yellowstone Induction Study # 2 OZANIMOD in Moderate to Severe CD (RPC01-3202) (BMS Study Number: IM047-P15) (RPC01-3202) $72,032 2 payments
9. MEDI9197 TLR7-8 Solid Tmr-D6410C00001 Phase 1 FTIH of MEDI-9197 in $71,924 1 payment
10. Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years) $70,088 83 payments

1. Non-patient care $49,854 6 payments
2. Overhead $16,215 2 payments
3. Other $12,565 8 payments
4. Patient care $11,987 7 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.